Table 2 AEs leading to discontinuation that occurred in >1.0% of patients in the 23 mg/d treatment group
From: Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
Preferred Term | Donepezil 23 mg/d, n (%) (n = 963) | Donepezil 10 mg/d, n (%) (n = 471) |
|---|---|---|
Total | 179 (18.6) | 37 (7.9) |
Vomiting | 28 (2.9) | 2 (0.4) |
Nausea | 18 (1.9) | 2 (0.4) |
Diarrhea | 16 (1.7) | 2 (0.4) |
Dizziness | 11 (1.1) | 0 (0.0) |